MALDI-8020: Small size. Massive impact
The MALDI-8020 is the latest in a long line of MALDI-TOF products from Shimadzu. This benchtop, linear MALDI-TOF mass spectrometer delivers outstanding performance in a compact footprint, making it an ideal choice for today’s increasingly demanding laboratories.
The MALDI-8020 is the latest in a long line of MALDI-TOF products from Shimadzu. This benchtop, linear MALDI-TOF mass spectrometer delivers outstanding performance in a compact footprint, making it an ideal choice for today’s increasingly demanding laboratories.
Key features:
- Linear mode (positive ion) MALDI-TOF
- 200 Hz solidâstate laser, 355 nm
- Load-lock chamber for fast sample introduction
- UV laserâbased source cleaning (patented)
- Small size due to benchtop design with a compact footprint
- Quiet operation (<55 dB)
Linear mode instruments have traditionally been the instruments of choice in MALDI-TOF-based quality control (QC) and profiling workflows, and the MALDI-8020 is no exception. Peptides, proteins, polymers or oligonucleotides â the instrument is capable of delivering the performance required for QC applications. Research laboratories will also benefit from the MS capabilities of the instrument through the rapid mass-measurement of samples.
Contact Details:
Company Name: Shimadzu Europa GmbH
Website: www.shimadzu.eu
Email: shimadzu@shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
